Company / R&D Expense
Prime Medicine, Inc. R&D Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$155.3M
FY2024
5-year range
$3.0M / $155.3M
FY2020-FY2024
Trend
+5.0%
vs FY2023
Sector context
#100 of 208
Health Care
What the data says
At $155M, Prime Medicine, Inc.'s r&d expense ranks #100 of 208 in the Health Care sector. R&D Expense has increased for 4 consecutive years, from $3M in FY2020 to $155M in FY2024.
Based on SEC 10-K filings.
$155M in FY2024 with a 3-year CAGR of +30.1%.
Improved from $87M to $155M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +30.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#100 of 208 in Health CareTop 48% of 208This company $155.3M Sector average $644.3M
▼
-75.9% below sector average
Key checks
Key Insights
- Prime Medicine, Inc.'s r&d expense has grown for 4 consecutive years.
- 3-year CAGR of +30.1%, indicating consistent growth.
- In FY2024, r&d expense increased 5.0% year-over-year.
- Ranks #100 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.24 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $155.3M | +5.0% |
| FY2023 | $147.9M | +70.5% |
| FY2022 | $86.7M | +22.9% |
| FY2021 | $70.5M | +2267.4% |
| FY2020 | $3.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026